{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:49:47Z","timestamp":1760921387841,"version":"build-2065373602"},"reference-count":95,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,1,2]],"date-time":"2016-01-02T00:00:00Z","timestamp":1451692800000},"content-version":"vor","delay-in-days":1310,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"crossref","award":["V101C-128","V101E4-004","V101E5-006"],"award-info":[{"award-number":["V101C-128","V101E4-004","V101E5-006"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001868","name":"National Science Council of Taiwan","doi-asserted-by":"crossref","award":["NSC 99-2314-B-010-009-MY3"],"award-info":[{"award-number":["NSC 99-2314-B-010-009-MY3"]}],"id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.tjog.2012.04.001","type":"journal-article","created":{"date-parts":[[2012,7,12]],"date-time":"2012-07-12T21:12:25Z","timestamp":1342127545000},"page":"153-166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Osteoporosis treatment in postmenopausal women with pre-existing fracture"],"prefix":"10.1016","volume":"51","author":[{"given":"Ming-Huei","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Fu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Ling","family":"Fuh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Ling","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng-Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjog.2012.04.001_bib1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2005.12.017","article-title":"Preventing osteoporosis-related fractures: an overview","volume":"119","author":"Gass","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.tjog.2012.04.001_bib2","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s11926-010-0097-y","article-title":"The societal burden of osteoporosis","volume":"12","author":"Becker","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.tjog.2012.04.001_bib3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00198-004-1811-2","article-title":"Requirements for DXA for the management of osteoporosis in Europe","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.tjog.2012.04.001_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00774-006-0720-1","article-title":"Osteoporotic fractures in Asia: risk factors and strategies for prevention","volume":"25","author":"Liu","year":"2007","journal-title":"J Bone Miner Metab"},{"unstructured":"The Taiwanese Osteoporosis Association. Osteoporosis management- guideline and consensus. The Taiwan Osteoporosis Association. Published date: 27\/03\/2012. Access date: 16\/06\/2012. (http:\/\/www.toa1997.org.tw\/index.php?page_id=9bf31c7ff062936a96d3c8bd1f8f2ff3&mod=bulletin_edit&id=356).","key":"10.1016\/j.tjog.2012.04.001_bib5"},{"key":"10.1016\/j.tjog.2012.04.001_bib6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bone.2008.09.004","article-title":"A nationwide seven-year trend of hip fractures in the elderly population of Taiwan","volume":"44","author":"Shao","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.tjog.2012.04.001_bib7","article-title":"In the clinic","volume":"155","author":"Lewiecki","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.tjog.2012.04.001_bib8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1517\/14728214.13.1.119","article-title":"Uterine myoma: A condition amendable to medical therapy?","volume":"13","author":"Cheng","year":"2008","journal-title":"Expert Opinion Emerging Drugs"},{"key":"10.1016\/j.tjog.2012.04.001_bib9","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S1028-4559(09)60295-3","article-title":"Adenomyosis and its variance: adenomyoma and female fertility","volume":"48","author":"Wang","year":"2009","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2012.04.001_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1028-4559(10)60001-0","article-title":"Chemotherapy induced gonadotoxicity","volume":"49","author":"Wang","year":"2010","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2012.04.001_bib11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1028-4559(07)60006-0","article-title":"Standard and low-dose hormone therapy for postmenopausal women-Focus on the breast","volume":"46","author":"Wang","year":"2007","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2012.04.001_bib12","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1726-4901(08)70041-8","article-title":"Transdermal 17\u03b2-estradiol for preventing postmenopausal bone loss","volume":"70","author":"Lee","year":"2007","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2012.04.001_bib13","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jcma.2011.04.001","article-title":"Borderline ovarian tumor and future fertility","volume":"74","author":"Tsui","year":"2011","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.tjog.2012.04.001_bib14","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1016\/j.fertnstert.2009.11.038","article-title":"Basal follicle-stimulating hormone level changes after different types of uterine vessel occlusion in the management of uterine fibroids","volume":"94","author":"Lee","year":"2010","journal-title":"Fertil Steril"},{"key":"10.1016\/j.tjog.2012.04.001_bib15","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.fertnstert.2011.06.033","article-title":"A cohort study to evaluate the effectiveness of laparoscopic-guided local injection with etoposide in the management of women with unruptured tubal pregnancy","volume":"96","author":"Chen","year":"2011","journal-title":"Fertil Steril"},{"key":"10.1016\/j.tjog.2012.04.001_bib16","doi-asserted-by":"crossref","first-page":"544","DOI":"10.4158\/EP.9.6.544","article-title":"American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003","volume":"9","author":"Hodgson","year":"2003","journal-title":"Endocr Pract"},{"key":"10.1016\/j.tjog.2012.04.001_bib17","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S8756-3282(99)00202-1","article-title":"Association of prevalent vertebral fractures, bone density, and alendronate treatment with incident vertebral fractures: effect of number and spinal location of fractures. The Fracture Intervention Trial Research Group","volume":"25","author":"Nevitt","year":"1999","journal-title":"Bone"},{"key":"10.1016\/j.tjog.2012.04.001_bib18","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1359\/jbmr.2000.15.4.721","article-title":"Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis","volume":"15","author":"Klotzbuecher","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.tjog.2012.04.001_bib19","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1359\/jbmr.1999.14.5.821","article-title":"Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group","volume":"14","author":"Black","year":"1999","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.tjog.2012.04.001_bib20","doi-asserted-by":"crossref","first-page":"919","DOI":"10.7326\/0003-4819-114-11-919","article-title":"Pre-existing fractures and bone mass predict vertebral fracture incidence in women","volume":"114","author":"Ross","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.tjog.2012.04.001_bib21","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jama.285.3.320","article-title":"Risk of new vertebral fracture in the year following a fracture","volume":"285","author":"Lindsay","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.tjog.2012.04.001_bib22","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.tjog.2012.04.001_bib23","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/BF01623272","article-title":"Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women","volume":"3","author":"Ross","year":"1993","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.tjog.2012.04.001_bib24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.tjog.2012.04.001_bib25","first-page":"392","article-title":"Bisphosphonates, hypercalcemia of malignancy, and osteonecrosis of the jaw","volume":"53","author":"Wynn","year":"2005","journal-title":"Gen Dent"},{"key":"10.1016\/j.tjog.2012.04.001_bib26","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.1542\/peds.2006-2023H","article-title":"Bisphosphonates: mode of action and pharmacology","volume":"119","author":"Russell","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.tjog.2012.04.001_bib27","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.mrfmmm.2005.02.028","article-title":"Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance","volume":"591","author":"Lewis","year":"2005","journal-title":"Mutation Research"},{"key":"10.1016\/j.tjog.2012.04.001_bib28","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.maturitas.2008.04.009","article-title":"Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women","volume":"60","author":"Lee","year":"2008","journal-title":"Maturitas"},{"key":"10.1016\/j.tjog.2012.04.001_bib29","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S1028-4559(08)60051-0","article-title":"The role of selective estrogen receptor modulator on breast cancer-from tamoxifen to raloxifene","volume":"47","author":"Lee","year":"2008","journal-title":"Taiwan J Obstet Gynecol"},{"key":"10.1016\/j.tjog.2012.04.001_bib30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1055\/s-0030-1248255","article-title":"Back to the future: revisiting parathyroid hormone and calcitonin control of bone remodeling","volume":"42","author":"de Paula","year":"2010","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.tjog.2012.04.001_bib31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0022-5320(72)90017-2","article-title":"Ultrastructural effects of calcitonin on osteoclasts in tissue culture","volume":"39","author":"Kallio","year":"1972","journal-title":"J Ultrastruct Res"},{"key":"10.1016\/j.tjog.2012.04.001_bib32","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.bone.2005.07.029","article-title":"Strontium ranelate: a physiological approach for optimizing bone formation and resorption","volume":"38","author":"Marie","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.tjog.2012.04.001_bib33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bone.2007.08.043","article-title":"Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in\u00a0vitro","volume":"42","author":"Bonnelye","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.tjog.2012.04.001_bib34","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/jbmr.5650080512","article-title":"An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats","volume":"8","author":"Marie","year":"1993","journal-title":"J Bone Miner Res"},{"unstructured":"Committee for Medicinal Products for Human Use. Protelos: EPAR-Scientific Discussion. European Medicines Agency. Published date: 21\/11\/2005. Access date: 16\/06\/2012. (http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Scientific_Discussion\/human\/000560\/WC500045522.pdf).","key":"10.1016\/j.tjog.2012.04.001_bib35"},{"key":"10.1016\/j.tjog.2012.04.001_bib36","first-page":"690","article-title":"Anabolic actions of parathyroid hormone on bone","volume":"14","author":"Dempster","year":"1993","journal-title":"Endocr Res"},{"key":"10.1016\/j.tjog.2012.04.001_bib37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/jbmr.5650070110","article-title":"Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone","volume":"7","author":"Hock","year":"1992","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.tjog.2012.04.001_bib38","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.tjog.2012.04.001_bib39","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.tjog.2012.04.001_bib40","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF01623271","article-title":"Prevalence and incidence of vertebral deformities","volume":"3","author":"Melton","year":"1993","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.tjog.2012.04.001_bib41","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.tjog.2012.04.001_bib42","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s00198-004-1602-9","article-title":"Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study","volume":"15","author":"Delmas","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.tjog.2012.04.001_bib43","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","article-title":"A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group","volume":"109","author":"Chesnut","year":"2000","journal-title":"Am J Med"},{"key":"10.1016\/j.tjog.2012.04.001_bib44","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","article-title":"The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis","volume":"350","author":"Meunier","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjog.2012.04.001_bib45","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/art.23461","article-title":"Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial","volume":"58","author":"Reginster","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.tjog.2012.04.001_bib46","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjog.2012.04.001_bib47","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S8756-3282(02)00869-4","article-title":"Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis","volume":"31","author":"Eriksen","year":"2002","journal-title":"Bone"},{"key":"10.1016\/j.tjog.2012.04.001_bib48","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00223-004-0039-7","article-title":"Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis","volume":"75","author":"Ste-Marie","year":"2004","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.tjog.2012.04.001_bib49","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1359\/JBMR.050309","article-title":"Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters","volume":"20","author":"Arlot","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.tjog.2012.04.001_bib50","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1359\/jbmr.090315","article-title":"Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis","volume":"24","author":"Recker","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.tjog.2012.04.001_bib51","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S8756-3282(02)00946-8","article-title":"Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience","volume":"32","author":"Sorensen","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.tjog.2012.04.001_bib52","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1210\/jc.2002-020400","article-title":"Risedronate prevents new vertebral fractures in postmenopausal women at high risk","volume":"88","author":"Watts","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.tjog.2012.04.001_bib53","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.tjog.2012.04.001_bib54","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00198-007-0530-x","article-title":"Back pain in osteoporotic vertebral fractures","volume":"19","author":"Francis","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.tjog.2012.04.001_bib55","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00198-007-0464-3","article-title":"Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis","volume":"19","author":"Marquis","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.tjog.2012.04.001_bib56","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s00198-008-0825-6","article-title":"Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis","volume":"20","author":"Meunier","year":"2009","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.tjog.2012.04.001_bib57","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1007\/s00198-006-0177-z","article-title":"Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis","volume":"17","author":"Nevitt","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.tjog.2012.04.001_bib58","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s00223-009-9299-6","article-title":"Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS)","volume":"85","author":"Langdahl","year":"2009","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.tjog.2012.04.001_bib59","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1185\/03007995.2010.488516","article-title":"Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS","volume":"26","author":"Lyritis","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.tjog.2012.04.001_bib60","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/PL00004151","article-title":"Measuring quality of life in women with osteoporosis","volume":"7","author":"Osteoporosis Quality of Life Study Group","year":"1997","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.tjog.2012.04.001_bib61","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1002\/1529-0131(200111)44:11<2611::AID-ART441>3.0.CO;2-N","volume":"44","author":"Silverman","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.tjog.2012.04.001_bib62","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00198-008-0674-3","article-title":"Design of the POSSIBLE USTM Study: postmenopausal women\u2019s compliance and persistence with osteoporosis medications","volume":"20","author":"Barrett-Connor","year":"2009","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.tjog.2012.04.001_bib63","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1185\/03007991003633603","article-title":"Gastrointestinal side effects in postmenopausal women using osteoporosis therapy: 1-year findings in the POSSIBLE US study","volume":"26","author":"Woo","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.tjog.2012.04.001_bib64","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","article-title":"Esophagitis associated with the use of alendronate","volume":"335","author":"de Groen","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjog.2012.04.001_bib65","first-page":"1377","article-title":"Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis","volume":"4","author":"Ettinger","year":"1998","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.tjog.2012.04.001_bib66","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/jama.2010.1098","article-title":"Exposure to oral bisphosphonates and risk of esophageal cancer","volume":"304","author":"Cardwell","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.tjog.2012.04.001_bib67","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMc0808738","article-title":"Reports of esophageal cancer with oral bisphosphonate use","volume":"360","author":"Wysowski","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjog.2012.04.001_bib68","doi-asserted-by":"crossref","first-page":"23","DOI":"10.14219\/jada.archive.2008.0016","article-title":"Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people","volume":"139","author":"Cartsos","year":"2008","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.tjog.2012.04.001_bib69","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00198-007-0502-1","article-title":"Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker","volume":"19","author":"Pazianas","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.tjog.2012.04.001_bib70","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.amjmed.2008.12.004","article-title":"Safety of bisphosphonates in the treatment of osteoporosis","volume":"122","author":"Recker","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.tjog.2012.04.001_bib71","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00223-010-9364-1","article-title":"Adverse effects of bisphosphonates","volume":"86","author":"Abrahamsen","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.tjog.2012.04.001_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004720","article-title":"Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis","volume":"4","author":"Grosso","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.tjog.2012.04.001_bib73","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1359\/jbmr.070112","article-title":"Alendronate treatment in women with normal to severely impaired renal function: an analysis of the Fracture Intervention Trial","volume":"22","author":"Jamal","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.tjog.2012.04.001_bib74","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jc.2009-1947","article-title":"Long-term use of bisphosphonates in osteoporosis","volume":"95","author":"Watts","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.tjog.2012.04.001_bib75","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American society for bone and mineral research","volume":"25","author":"Shane","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.tjog.2012.04.001_bib76","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S1028-4559(08)60149-7","article-title":"To switch or not to switch: should the study of tamoxifen and raloxifene (STAR) trial alter our decision?","volume":"47","author":"Wang","year":"2008","journal-title":"Taiwan J\u00a0Obstet Gynecol"},{"key":"10.1016\/j.tjog.2012.04.001_bib77","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1006478317173","article-title":"Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial","volume":"65","author":"Cauley","year":"2001","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.tjog.2012.04.001_bib78","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jnci\/djh319","article-title":"Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene","volume":"96","author":"Martino","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.tjog.2012.04.001_bib79","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1185\/030079905X61839","article-title":"Safety assessment of raloxifene over eight years in a clinical trial setting","volume":"21","author":"Martino","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.tjog.2012.04.001_bib80","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00019053-200725110-00003","article-title":"The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature","volume":"25","author":"Fleurence","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.tjog.2012.04.001_bib81","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1586\/erp.10.53","article-title":"Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis","volume":"10","author":"Hiligsmann","year":"2010","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.tjog.2012.04.001_bib82","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.bone.2009.08.052","article-title":"Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years","volume":"46","author":"Hiligsmann","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.tjog.2012.04.001_bib83","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.bone.2010.07.024","article-title":"Identifying cost-effective treatment with raloxifene in postmenopausal women using risk algorithms for fractures and invasive breast cancer","volume":"47","author":"Iverg\u00e5rd","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.tjog.2012.04.001_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta9220","article-title":"A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis","volume":"9","author":"Stevenson","year":"2005","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.tjog.2012.04.001_bib85","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"285","author":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.tjog.2012.04.001_bib86","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1007\/s00198-002-1345-4","article-title":"Bone strength and its determinants","volume":"14","author":"Ammann","year":"2003","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.tjog.2012.04.001_bib87","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jbmr.5650040214","article-title":"Increased incidence of hip fracture in osteoporotic women treated with sodium fluoride","volume":"4","author":"Hedlund","year":"1989","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.tjog.2012.04.001_bib88","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s001980050041","article-title":"Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOStudy","volume":"8","author":"Meunier","year":"1998","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.tjog.2012.04.001_bib89","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1056\/NEJM199003223221203","article-title":"Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis","volume":"322","author":"Riggs","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjog.2012.04.001_bib90","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/00003086-199012000-00032","article-title":"Bone fragility of the peripheral skeleton during fluoride therapy for osteoporosis","volume":"261","author":"Schnitzler","year":"1990","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.tjog.2012.04.001_bib91","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.maturitas.2005.06.001","article-title":"Attitudes toward menopause among middle-aged women: a community survey in an island of Taiwan","volume":"52","author":"Cheng","year":"2005","journal-title":"Maturitas"},{"key":"10.1016\/j.tjog.2012.04.001_bib92","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/gme.0b013e3180333a58","article-title":"Does menopausal transition affect the quality of life? A longitudinal study of middle-aged women in Kinmen","volume":"14","author":"Cheng","year":"2007","journal-title":"Menopause"},{"key":"10.1016\/j.tjog.2012.04.001_bib93","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1210\/jc.2006-1404","article-title":"Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials","volume":"92","author":"Boonen","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.tjog.2012.04.001_bib94","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1080\/10408390701407266","article-title":"Review of the dietary reference intake for calcium: where do we go from here?","volume":"48","author":"Meacham","year":"2008","journal-title":"Crit Rev Food Sci Nutr"},{"key":"10.1016\/j.tjog.2012.04.001_bib95","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1210\/jc.2008-0926","article-title":"National Osteoporosis Foundation Guide Committee. A revised clinician's guide to the prevention and treatment of osteoporosis","volume":"93","author":"Dawson-Hughes","year":"2008","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455912000575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455912000575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T18:10:07Z","timestamp":1760897407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1028455912000575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":95,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S1028455912000575"],"URL":"https:\/\/doi.org\/10.1016\/j.tjog.2012.04.001","relation":{},"ISSN":["1028-4559"],"issn-type":[{"type":"print","value":"1028-4559"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osteoporosis treatment in postmenopausal women with pre-existing fracture","name":"articletitle","label":"Article Title"},{"value":"Taiwanese Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjog.2012.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}